Does Lobular Neoplasia Diagnosed on Core Biopsy Warrant Further Investigation? by Burr, Tucker et al.
Lehigh Valley Health Network
LVHN Scholarly Works
USF-LVHN SELECT
Does Lobular Neoplasia Diagnosed on Core
Biopsy Warrant Further Investigation?
Tucker Burr
USF MCOM-LVHN Campus, Tucker.Burr@lvhn.org
Ryan Lutz
USF MCOM-LVHN Campus, ryan.lutz@lvhn.org
Priya Sareen MD
Lehigh Valley Health Network, Priya_K.Sareen@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/select-program
Part of the Medical Education Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Burr, T. Lutz, R. Sareen, P. (2017, March). Does Lobular Neoplasia Diagnosed on Core Biopsy Warrant Further Investigation? Poster
Presented at: 2017 SELECT Capstone Posters and Presentations Day. Kasych Family Pavilon, Lehigh Valley Health Network,
Allentown, PA.




Conclusions and Future Implications
 
Lobular Neoplasia (LN) is an incidental finding 
on breast biopsy which represents a collection 
of round, monomorphic, dyshesive cells with 
increased cytoplasmic nuclear ratio. LN is classified 
as a range from Atypical Lobular Hyperplasia (ALH) 
to Lobular Carcinoma In-Situ (LCIS). These lesions 
are known to have an associated higher relative 
risk of subsequent carcinoma bilaterally (eight-to-
nine fold and four-to-five fold increases for LCIS 
and ALH, respectively). While numerous past studies 
have shown a high upgrade rate to cancer of 10-
40%, these studies may be limited. Newer studies 
show a rate of 1-3%. Institutional protocols have 
recently changed such that close clinical follow-up 
of LN is warranted instead of excisional biopsy. 
 
A total of 1271 patient cases were reviewed from the radiology technician log. Females comprised 97.7% of 
patients. Ultrasound biopsy guidance was performed in 75% of cases compared with 25% using stereotactic 
(Table 1, Figure 1). Biopsy was not performed on 67 cases, and core biopsy results were reviewed in 1204 
cases. LN as the highest-risk lesion was found in 15 cases (4 were LCIS and 11 were ALH), equivalent to 
1.3% of all cases (Table 2). Of the 15 cases with LN, 12 elected to have excisional biopsy at LVHN of which 2 
(17%) were upgraded to a cancer diagnosis (Table 3). 
 By determining the baseline upgrade rate from LN on core biopsy to cancer at excision biopsy for 
women at Lehigh Valley Health Network (LVHN), we 
can compare to the upgrade rate in recent literature 
and have a better understanding of the risks of LN 
within the LVHN population. 
 
There is no clear consensus regarding the implications of LN and future management when it is the highest-
risk lesion found at core biopsy. The patients in this study had core biopsies with LN as the highest-risk lesion 
in 15 cases, or 1.3% of cases, which is on-par with past studies (between 0.5 and 3.8%). Out of LN cases that 
underwent excisional biopsy, upgrade to cancer occurred in 2 (17%). While this is high, these 2 cases would 
heavily favor excision regardless of the diagnosis of LN due to discordant imaging and pathology. Overall, these 
results support the current protocol of close imaging follow-up, and further discussion in accordance with the 
patient’s goals. 
Methodology
 This study is a retrospective review of 27 months of stereotactic and ultrasound guided core biopsies. 
Biopsy cases were identified through logs kept by 
radiology technicians at Breast Health Services at 
LVHN. Cases were determined to be ineligible for 
the study if a biopsy was started but not completed 
or if the procedure was a cyst or hematoma 
drainage. Each case was reviewed for LN within the 
pathology report of the Electronic Medical Record 
(EMR). LN was noted if it was found to be the 
highest-risk lesion on core biopsy. If LN was found, 
the case was then checked for a follow-up surgical 
excisional biopsy. If there was an excisional biopsy, 
it was determined whether the lesion was upgraded 
to cancer according to the pathology report within 
the EMR. This study was determined by the project 
team to be exempt from Internal Review Board (IRB) 
approval because it was recorded in such a manner 
where subjects cannot be identified, it has no risk 
to patients, it involves the collection of existing data, 
and it seeks to improve the management of LN at 
LVHN while comparing to the established standard. 
Table 1. Demographic Data and Baseline Characteristics
Parameter Sample (N=1271)% (N)
Gender
   Female 99.7 (1267)
   Male 0.3 (4)
Biopsy Guidance Method
   Sonographic 75 (957)
   Stereotactic 25 (314)
Table 2. Core Biopsy Results
Parameter Sample (N=1204)% (N)
Results of Core Biopsy
   Not Lobular Neoplasia* 98.7 (1185)
   Concordant Lobular Neoplasia 1.3 (15)
        ALH 0.9 (11)
        LCIS 0.3 (4)
Figure 1. Consort Diagram
Table 2. Excisional Biopsy Results of Lesions with LN
Parameter Sample (N=12)% (N)
Preoperative Diagnosis (core biopsy)
        ALH 75 (9)
        LCIS 25 (3)
Postoperative Diagnosis (excisional biopsy)
        Cancer (upgrade) 17/(2)
        Same as preoperative 
        diagnosis (no upgrade) 83 (10)
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*Either no LN, or LN is compounded by a worse non-benign lesion 
of the breast.
